AMTI Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 gruod. 2023 @ 22:59):

Stats
Šios dienos apimtis	235 210
Vidutinė apimtis	320 195
Rinkos kapitalizacija	11.01M
EPS	$0 ( 2024-03-14 )
Kita pelno data	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.139
ATR14	$0.0200 (7.60%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-27	Epiq Capital Group, Llc	Sell	2 149 292	Common Stock
2023-12-27	Epiq Capital Group, Llc	Sell	3 394 948	Common Stock
2023-12-27	Epiq Capital Group, Llc	Sell	2 500 000	Common Stock
2023-12-27	Epiq Capital Group, Llc	Sell	293 278	Common Stock
2023-12-27	Vandevender Aaron	Sell	212 659	Common Stock

INSIDER POWER
-68.14
Last 100 transactions
Buy: 3 477 833 \| Sell: 13 394 035

Tūris Koreliacija

Ilgas: 0.02 (neutral)

Trumpas: 0.79 (moderate)

Signal:(62.898) Neutral

Applied Molecular Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
WOOF	0.969
WKEY	0.967
JAN	0.961
NMRD	0.96
MTLS	0.958
PODD	0.957
QRTEA	0.956
STIM	0.956
GERN	0.955
ENNV	0.955

10 Labiausiai neigiamai susiję koreliacijos
IGTA	-0.965
NVCN	-0.953
OHAA	-0.952
LCA	-0.951
TIOA	-0.949
BRIVU	-0.949
FTII	-0.949
HDSN	-0.948
MSDA	-0.946
CBRG	-0.941

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Applied Molecular Koreliacija - Valiuta/Žaliavos

0.84
( strong )

0.32
( neutral )

0.00
( neutral )

0.67
( moderate )

-0.21
( neutral )

-0.86
( strong negative )

Applied Molecular Finansinės ataskaitos

Annual	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-3.23

FY	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-3.23

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-4.38

FY	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.91

Financial Reports:

No articles found.

Applied Molecular

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.